# 229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB

**Channel:** Peter Attia MD
**Upload Date:** 2022-10-31
**URL:** https://www.youtube.com/watch?v=UWQsbBZHHUU
**Duration:** 78 minutes

## Description

Watch the full episode and view show notes here: https://bit.ly/3FwAC0p
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

In this special episode of The Drive, we have pulled together a variety of clips from previous podcasts about cardiovascular disease to help listeners understand this topic more deeply, as well as to identify previous episodes which may be of interest. In this episode, Peter highlights the importance of understanding cardiovascular disease and why early intervention is critical. He also provides a primer on lipoproteins and explains the fallacy of the terms “good cholesterol” and “bad cholesterol.” Allan Sniderman discusses the metrics measured in routine blood work – along with the limitations of those standard panels – before explaining why apoB is a superior metric for determining risk. Additionally, Tom Dayspring explains the casual role of apoB in atherosclerotic cardiovascular disease (ASCVD) and the therapeutic goals for apoB concentration, and Peter explains how early and aggressive lowering of apoB could change the landscape of cardiovascular disease prevention.


We discuss:
-Intro [0:00]
-The importance of understanding atherosclerosis early in life [2:25];
-Defining ASCVD, its causes, and the role of cholesterol [8:00];
-Why early prevention of atherosclerosis is critical [13:45];
-Preventing atherosclerosis—two fatal flaws with the “10-Year Risk” approach [16:00];
-Intro to lipids and lipoproteins: why there is no “bad” or “good” cholesterol [23:00];
-Limitations of standard blood panels [35:45]; 
-How Mendelian randomization is bolstering the case for apoB as the superior metric for risk prediction [39:30];
-Therapeutic goals for apoB concentration [58:15];
-How early and aggressive lowering of apoB could change the course of ASCVD [1:10:45]; and
-More.

--------
About:

The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 45 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.

## AI Summary

Here's a comprehensive analysis of this episode of The Drive podcast:

1. **Executive Summary**:
This special episode compiles clips from previous episodes focusing on atherosclerotic cardiovascular disease (ASCVD), cholesterol, and apoB. The discussion emphasizes why ASCVD is the only inevitable disease of our species, the importance of early intervention, and why apoB is a superior metric for assessing cardiovascular risk compared to traditional cholesterol measurements.

2. **Key Medical/Scientific Points**:
- ASCVD is inevitable in humans who live long enough [00:03:38]
- Over 50% of first heart attacks are fatal [00:06:04]
- Over 50% of men will have their first cardiac event before age 65 [00:06:04]
- Women experience cardiac events about a decade later than men [00:06:04]
- Atherosclerosis begins with fatty streaks and develops into plaques [00:08:31]
- ApoB is a superior predictor of cardiovascular risk compared to LDL-C [01:03:02]

3. **Health Optimization Tips**:

Universal Recommendations:
- Consider early intervention for apoB reduction [01:16:03]
- Monitor apoB levels starting in late 30s/early 40s [01:16:03]

Context-specific recommendations:
- Target apoB levels below 60 mg/dL (5th percentile) [01:08:54]
- Consider more aggressive treatment if calcium score is positive [01:14:00]

4. **Supplements & Medications**:
- Statins mentioned for lipid management [00:57:51]
- PCSK9 inhibitors discussed for achieving very low apoB levels [01:06:13]

5. **Biomarkers & Testing**:
- ApoB concentration [00:34:02]
- Coronary calcium score [01:07:55]
- LDL-C and HDL-C [00:34:29]
- Total cholesterol [01:07:55]
- Triglycerides [00:39:24]

6. **Notable Quotes**:
"No cholesterol, no life, period." [00:12:18]

"Atherosclerosis is really the only inevitable disease of our species." [00:03:38]

7. **Follow-up Questions**:
1. What is the optimal timing for beginning apoB reduction therapy in different risk groups?
2. How does the benefit/risk ratio change at different apoB levels?
3. What role does genetics play in determining individual response to lipid-lowering interventions?

This analysis captures the main points but there's much more detail in the transcript. Would you like me to expand on any particular section?
